Search Results for "hansten"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for hansten. Results 201 to 210 of 433 total matches.
Dofetilide for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • May 15, 2000 (Issue 1078)
D. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel, M.D., Albert Einstein College ...
Dofetilide (Tikosyn - Pfizer), a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and flutter.
Drugs that may cause Cognitive Disorders in the Elderly
The Medical Letter on Drugs and Therapeutics • Nov 27, 2000 (Issue 1093)
.
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel, M.D., Albert ...
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.
Lopinavir/Ritonavir: A Protease-inhibitor Combination
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001 (Issue 1095)
Reiss, Ph.D.
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H ...
Lopinavir/ritonavir is the first fixed-dose combination of protease inhibitors approved by the FDA for the treatment of HIV infection. It is being marketed for use with other drugs in adults and children more than six months old. Lopinavir is a new drug available only in this combination. Ritonavir is often used with other protease inhibitors to raise their plasma concentrations.
Nebulized Budesonide For Asthma in Children
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001 (Issue 1096)
Reiss, Ph.D.
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H ...
The FDA has approved a nebulized suspension of the corticosteroid budesonide for maintenance treatment of persistent asthma in children one to eight years old.
Bivalirudin (Angiomax) For Angioplasty
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001 (Issue 1103)
Goodstein, Amy Faucard
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H ...
Bivalirudin is being promoted as an intravenous (IV) anticoagulant that can be used instead of heparin in patients with unstable angina undergoing coronary angioplasty.
Pegylated Interferon (PEG-Intron) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001 (Issue 1107)
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel, M.D., Albert ...
Recombinant interferon alfa-2b conjugated to polyethylene glycol (PEG-Intron), the first "pegylated"alpha interferon, has been approved by the FDA for once-a-week monotherapy of chronic hepatitis C virus (HCV) infection in patients not previously treated with alpha interferon.
Echinacea for Prevention and Treatment of Upper Respiratory Infections
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002 (Issue 1127)
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel, M.D., Albert ...
Echinacea, a plant also called purple coneflower, is widely used as a dietary supplement for prevention and treatment of colds.
Fondaparinux (Arixtra), A New Anticoagulant
The Medical Letter on Drugs and Therapeutics • May 13, 2002 (Issue 1130)
Wong
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D., University of Washington; Neal H. Steigbigel ...
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip replacement.
Fulvestrant (Faslodex) for Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jul 22, 2002 (Issue 1135)
Goodstein, Amy Faucard ASSISTANT EDITOR: Susie Wong
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D ...
Fulvestrant (Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast cancer in postmenopausal women with disease progession on tamoxifen (Nolvadex, and others) or another antiestrogen.
Alefacept (Amevive) For Treatment of Psoriasis
The Medical Letter on Drugs and Therapeutics • Apr 14, 2003 (Issue 1154)
: Martin A. Rizack, M.D., Ph.D., Rockefeller University
CONTRIBUTING EDITORS: Philip D. Hansten, Pharm. D ...
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.